Department of Oncology of the Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zheng Zhou, Henan Province 450007, China.
Department of Oncology of the Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zheng Zhou, Henan Province 450007, China.
Crit Rev Oncol Hematol. 2024 Apr;196:104313. doi: 10.1016/j.critrevonc.2024.104313. Epub 2024 Feb 28.
Cancer is a major disease that endangers human health. Cancer drug resistance and relapse are the two main causes contributing to cancer treatment failure. Cancer stem cells (CSCs) are a small fraction of tumor cells that are responsible for tumorigenesis, metastasis, relapse, and resistance to conventional anticancer therapies. Therefore, CSCs are considered to be the root of cancer recurrence, metastasis, and drug resistance. Novel anticancer strategies need to face this new challenge and explore their efficacy against CSCs. Recently, immunotherapy has made rapid advances in cancer treatment, and its potential against CSCs is also an interesting area of research. Meanwhile, immunotherapy strategies are novel therapeutic modalities with promising results in targeting CSCs. In this review, we summarize the targeting of CSCs by various immunotherapy strategies such as monoclonal antibodies(mAb), tumor vaccines, immune checkpoint inhibitors, and chimeric antigen receptor-T cells(CAR-T) in pre-clinical and clinical studies. This review provides new insights into the application of these immunotherapeutic approaches to potential anti-tumor therapies in the future.
癌症是一种严重危害人类健康的疾病。癌症耐药和复发是导致癌症治疗失败的两个主要原因。癌症干细胞（CSCs）是肿瘤细胞中的一小部分，负责肿瘤的发生、转移、复发和对传统抗癌治疗的耐药性。因此，CSCs 被认为是癌症复发、转移和耐药的根源。新型抗癌策略需要面对这一新的挑战，并探索其对 CSCs 的疗效。最近，免疫疗法在癌症治疗方面取得了快速进展，其针对 CSCs 的潜力也是一个有趣的研究领域。同时，免疫疗法策略是一种新型的治疗方式，在针对 CSCs 方面具有很有前途的结果。在这篇综述中，我们总结了各种免疫治疗策略（如单克隆抗体（mAb）、肿瘤疫苗、免疫检查点抑制剂和嵌合抗原受体-T 细胞（CAR-T））在临床前和临床研究中针对 CSCs 的作用。这篇综述为这些免疫治疗方法在未来应用于潜在的抗肿瘤治疗提供了新的思路。
